secwatch.observer — SEC 8-K summary
======================================

Issuer:     Instil Bio, Inc. (TIL)
CIK:        0001789769
Form:       8-K
Filed at:   2023-06-26T23:59:59+00:00
Accession:  0001789769-23-000077
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Instil Bio preclinical data show FRα-CoStAR enhances TIL activity; clinical restart H2 2023
--------------------------------------------------------------------------------

- Oral presentation at BSGCT conference on ITIL-306 preclinical data.
- FRα-CoStAR enhanced TIL activity against autologous NSCLC, ovarian, and renal tumors.
- Enhanced activity exceeded melanoma TILs as measured by IFNγ secretion.
- ITIL-306 clinical study anticipated to resume in 2H 2023; initial clinical data expected in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789769/000178976923000077/0001789769-23-000077-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789769/000178976923000077/til-20230626.htm
  HTML page:      https://secwatch.observer/filing/0001789769-23-000077

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer